2020 in Review
• The AmSpa Aesthetic Safety Council (AASC), designed to help the American Med Spa Association (AmSpa) further its goal of promoting compliance, safety, and profitability throughout the medical aesthetic industry, has launched.
Even in the midst of the international COVID-19 pandemic, medical aesthetics remains one of the fastest-growing industries in the United States. The AASC consists of medical aesthetic industry professionals from different practice levels—including physicians, APRNs/NPs, RNs, PAs and owners—who will review and provide feedback on AmSpa’s recently released practice guidelines, as well as guide AmSpa to ensure that it is helping to make the medical aesthetic industry more compliant, more profitable and, ultimately, safer for patients. The AASC will also provide insight, feedback and “in the field” leadership for AmSpa. Read the full story.
Get more from AmSpa’s Alex Thiersch, JD, in the Nov/Dec 2020 edition of Modern Aesthetics® magazine.
• Revance Therapeutics, Inc. is introducing the RHA Collection of dermal fillers, Resilient Hyaluronic Acid, and the HintMD financial technology platform, in the US. Revance concluded the RHA Collection PrevU early clinical experience education and training program for select practices ahead of the consumer launch of the RHA Collection and plans to share observations in the near future. The same commercial infrastructure is anticipated to roll out DaxibotulinumtoxinA for Injection for the treatment of glabellar lines upon FDA approval. Revance recently announced that the decision date for doxibotulinumtoxinA has been delayed so that FDA can complete routine site visits. Read the full story.
• Endo Aesthetic’s Qwo (collagenase clostridium histolyticum-aaes) is the first injectable treatment for moderate to severe cellulite of the buttocks in adult women. Qwo, which targets and lyses collagen tethers to release the skin dimpling and smooth skin, is expected to be available throughout the United States at aesthetic healthcare practitioner's offices starting in Spring 2021. Read the full story.
Deanne Mraz Robinson, MD discussed the role of Qwo in the Nov/Dec 2020 edition of Modern Aesthetics.
• All of that Zoom has led to a boom in requests for facial plastic surgery, according to research led by Steve Dayan, MD and published in The Journal of Facial Plastic Surgery and Aesthetic Medicine.
As many as 55 percent of survey respondents expressed an increase in anxiety and self-consciousness about facial appearance, with the most common area of concern being the nose. Other areas of concern included acne breakouts, dark under-eye circles, crow’s feet, skin texture, and crepey necks. Read the full story.
• The FDA approved Allergan Aesthetics' Juvéderm Voluma XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. According to Allergan Aesthetics, an AbbVie company, the Juvéderm Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest approval marks their fifth approved indication in the US. Juvéderm Voluma XC is the first filler to receive US FDA approval for the augmentation of the chin region. Read the full story.
• There was a 15 percent decrease in breast augmentation surgery in 2019, according to new statistics from the Aesthetic Society. What’s more, breast implant removal increased by 34.4 percent in 2019. These statistics are likely driven by concerns about breast implant associated-anaplastic large cell lymphoma. To that end, The Aesthetic Society has launched new efforts to educate patients who have had or are exploring breast implant surgery. Read the full story.
Lisa B. Cassileth, MD, FACS provided a frank assessment of breast explantation in the July/August edition of Modern Aesthetics.
• AbbVie completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. In connection with the closing of the transaction, the AbbVie Board of Directors has elected Thomas C. Freyman, retired Executive Vice President and Chief Financial Officer, Abbott, to join the AbbVie board. Mr. Freyman recently served on the Allergan Board of Directors. Read the full story.
• The FDA approved Galderma'a Restylane Kysse for lip augmentation and the correction of upper perioral rhytids in adults over the age of 21. Restylane Kysse is the first hyaluronic acid (HA) filler specifically indicated for the lips using XpresHAn Technology globally referred to as the OBT technology (Optimal Balance Technology). According to Galderma, Restylane Kysse is proven to last for up to 1 year with high levels of patient satisfaction for people with lips that have changed due to the aging process or for those seeking natural-looking, fuller lips. Read the full story.
• Follow the latest developments in Energy-based Devices, including launches from BTL, Cutera, Cynosure, and others, on our website.
• For more on the impact of the COVID-19 pandemic on the aesthetics industry, visit our dedicated coverage online.